Viatris Inc. (VTRS) AI Stock Analysis

Viatris Inc. operates as a global healthcare company structured into four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company provides prescription brand drugs, generic drugs, complex generics, biosimilars, and active pharmaceutical ingredients (APIs). Its portfolio addresses various therapeutic areas, including noncommunicable and infectious diseases, oncology, immunology, endocrinology, ophthalmology, and dermatology. Key commercial products include Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, and Fulphila. Viatris delivers medications through retail pharmacies, wholesalers, institutional pharmacies, mail-order pharmacies, and specialty distributors across global markets.

Annual revenue declined over four consecutive fiscal years, moving from $17.89B in FY2021 to $16.26B in FY2022, $15.43B in FY2023, $14.74B in FY2024, and $14.30B in FY2025. Gross margin contracted from 41.7% in FY2023 to 35.1% in FY2025, while operating margin fell to -18.6% in FY2025, resulting in a net loss of -$3.51B. Research and development expense rose to $965.9M in FY2025. Over the trailing twelve months, revenue totaled $14.74B with an operating margin of 12.6% and a net margin of -2.8%. In the latest quarter ended June 30, 2026, quarterly revenue grew 4.9% year-over-year, while quarterly earnings declined 70.6%.

As of June 30, 2026, Viatris held $1.51B in cash and short-term investments against total debt of $13.63B, leaving net debt at $12.12B. Total assets stood at $35.04B, with shareholders' equity of $14.26B, yielding a debt-to-equity ratio of 0.96 and a current ratio of 1.58. Operating cash flow reached $2.32B in FY2025, supporting free cash flow of $1.94B. Capital allocation in FY2025 included $378.8M for capital expenditures, $500.5M spent on share buybacks, and $561.2M paid in dividends.

Viatris closed at $18.66 on October 16, 2026, representing a 53.4% gain year-to-date and a 91.3% one-year return, outpacing the S&P 500 benchmark return of 16.8% over the past year. The company carries a market cap of $21.43B and an enterprise value of $31.80B. Its forward P/E of 6.4x trades below the median of its S&P 500 Healthcare peers of 16.6x. Viatris also trades at a price-to-sales ratio of 1.5x and an EV-to-EBITDA of 11.9x, both below the peer medians of 3.4x and 15.7x, respectively.

Viatris pays a forward annual dividend of $0.48 per share, which equates to a dividend yield of 2.57%. The company distributes dividends on a quarterly frequency and has paid dividends for 6 consecutive years. In FY2025, total dividends paid were $561.2M, with a payout ratio of 19.1%. The stock's most recent ex-dividend date was August 21, 2026.

Wall Street sentiment covers 12 ratings, comprising 6 Strong Buy, 1 Buy, 4 Hold, and 1 Sell recommendations. The mean price target is $19.70, implying 5.6% upside over the last close of $18.66. Analysts project FY2026 revenue of $14.79B and EPS of $2.52, followed by FY2027 revenue of $15.04B and EPS of $2.68. Viatris has beaten consensus EPS estimates in 4 of its last 4 quarters, with the next earnings announcement scheduled for November 5, 2026.

This page is an AI-written research summary of Viatris Inc. (VTRS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: VTRS income statement, VTRS balance sheet, VTRS key metrics, VTRS analyst forecast, VTRS chart. See the VTRS stock overview for the latest quote and news.